Copyright
©The Author(s) 2025.
World J Psychiatry. Feb 19, 2025; 15(2): 99996
Published online Feb 19, 2025. doi: 10.5498/wjp.v15.i2.99996
Published online Feb 19, 2025. doi: 10.5498/wjp.v15.i2.99996
Table 1 Demographic and clinical information of patients with major depressive disorders
Items | Overall MDD group (n = 206) | Subgroup based on follow-up data | Sig. |
Age (years) | 23 (10) | 22 (9) | 0.132 |
Years of education | 14.52 ± 2.55 | 14.33 ± 2.66 | 0.530 |
BMI (kg/m2) | 22.02 ± 4.34 | 22.43 ± 4.78 | 0.424 |
Gender (female), No. (%) | 148 (71.8) | 87 (73.1) | 0.806 |
Marriage (unmarried), No. (%) | 156 (75.7) | 94 (79.0) | 0.713 |
Ethnicity (Han), No. (%) | 187 (90.8) | 109 (91.6) | 0.803 |
History of drinking, No. (%) | 39 (18.9) | 22 (18.5) | 0.983 |
History of smoking, No. (%) | 31 (15.0) | 17 (14.3) | 0.947 |
Depressive episodes | 2 (1) | 2 (1) | 0.493 |
HAMD-17 score at baseline | 21.24 ± 5.28 | 21.94 ± 5.05 | 0.557 |
HAMD-17 score at the end of follow-up1 | NA | 10.88 ± 7.12 | < 0.001a |
HAMA score at baseline | 21.38 ± 7.54 | 21.51 ± 7.58 | 0.883 |
HAMA score at the end of follow-up1 | NA | 11.69 ± 7.74 | < 0.001a |
BSSI score at baseline | 8.07 ± 7.68 | 7.57 ± 7.52 | 0.568 |
BSSI score at the end of follow-up1 (n = 66) | NA | 5.67 ± 7.10 | 0.004a |
SDS score at baseline | 18.50 ± 5.96 | 19.01 ± 6.07 | 0.466 |
SDS score at the end of follow-up1 | NA | 11.91 ± 7.57 | < 0.001a |
PDQ-5 score at baseline | 11.88 ± 3.54 | 11.69 ± 3.46 | 0.630 |
PDQ-5 score at the end of follow-up1 | NA | 8.27 ± 4.58 | < 0.001a |
Antidepressants at baseline | |||
SSRIs, No. (%) | 66 (32) | 43 (36.1) | 0.451 |
SNRIs, No. (%) | 20 (9.7) | 12 (10.1) | 0.913 |
SARIs, No. (%) | 98 (47.6) | 62 (52.1) | 0.432 |
Others2, No. (%) | 14 (6.8) | 7 (5.9) | 0.747 |
Antidepressants at the end of follow-up | |||
SSRIs, No. (%) | NA | 67 (32.5) | NA |
SNRIs, No. (%) | NA | 18 (8.7) | NA |
SARIs, No. (%) | NA | 86 (41.7) | NA |
Others2, No. (%) | NA | 21 (17.6) | NA |
Neuroticism score at baseline | 44.92 ± 5.97 | 45.05 ± 5.70 | 0.919 |
T-AI score at baseline | 59.98 ± 7.06 | 60.15 ± 6.80 | 0.824 |
PSS score at baseline | 24.76 ± 4.96 | 24.83 ± 5.28 | 0.899 |
S-AI score at baseline | 56.64 ± 8.67 | 56.47 ± 8.06 | 0.858 |
Table 2 Comparison of clinical manifestations at baseline and follow-up outcomes between major depressive disorders patients with high-level and low-level stress-sensitivity factors
Items | Groups | HAMD-17 at baseline | HAMD-17 at the end of follow-up | HAMA at baseline | HAMA at the end of follow-up | BSSI at baseline | BSSI at the end of follow-up | SDS at baseline | SDS at the end of follow-up | PDQ-5 at baseline | PDQ-5 at the end of follow-up |
Neuroticism | Low-level | 20.88 ± 5.42 | 9.54 ± 6.56 | 20.75 ± 7.65 | 10.31 ± 7.31 | 6.92 ± 7.04 | 4.23 ± 5.77 | 17.28 ± 6.01 | 10.90 ± 7.34 | 11.35 ± 3.47 | 7.34 ± 4.20 |
High-level | 22.10 ± 4.86 | 14.11 ± 7.46 | 22.83 ± 7.12 | 14.97 ± 7.87 | 10.74 ± 8.46 | 8.55 ± 8.64 | 21.35 ± 4.74 | 14.31 ± 7.68 | 13.11 ± 3.40 | 10.49 ± 4.75 | |
Sig. | 0.070 | 0.002a | 0.024a | 0.003a | 0.003a | 0.044a | < 0.001a | 0.035a | 0.001a | 0.001a | |
Trait anxiety | Low-level | 20.08 ± 5.05 | 9.17 ± 6.38 | 20.00 ± 6.94 | 9.95 ± 6.46 | 6.44 ± 6.21 | 4.19 ± 5.13 | 17.52 ± 6.18 | 10.79 ± 7.12 | 11.51 ± 3.61 | 7.38 ± 4.17 |
High-level | 24.76 ± 4.33 | 15.97 ± 6.88 | 25.55 ± 7.84 | 16.83 ± 8.98 | 13.04 ± 9.46 | 9.61 ± 9.86 | 21.49 ± 3.97 | 15.23 ± 7.99 | 13.02 ± 3.06 | 10.91 ± 4.79 | |
Sig. | < 0.001a | < 0.001a | < 0.001a | < 0.001a | < 0.001a | 0.038a | < 0.001a | 0.005a | 0.008a | < 0.001a | |
Perceived stress | Low-level | 20.08 ± 5.13 | 10.26 ± 7.05 | 20.00 ± 7.01 | 10.67 ± 7.45 | 6.76 ± 7.15 | 4.84 ± 5.80 | 17.48 ± 5.97 | 11.28 ± 7.35 | 11.36 ± 3.50 | 7.78 ± 4.59 |
High-level | 24.07 ± 4.54 | 12.44 ± 7.17 | 24.72 ± 7.80 | 14.23 ± 7.99 | 11.27 ± 8.04 | 7.32 ± 9.09 | 21.00 ± 5.16 | 13.47 ± 8.00 | 13.15 ± 3.31 | 9.50 ± 4.40 | |
Sig. | < 0.001a | 0.132 | < 0.001a | 0.023 | < 0.001a | 0.253 | < 0.001a | 0.155 | 0.001a | 0.063 | |
State anxiety | Low-level | 20.41 ± 5.13 | 10.23 ± 6.91 | 20.33 ± 7.44 | 10.59 ± 6.93 | 6.82 ± 6.89 | 5.20 ± 6.08 | 17.59 ± 6.04 | 11.38 ± 7.39 | 11.52 ± 3.59 | 7.80 ± 4.48 |
High-level | 23.98 ± 4.87 | 13.11 ± 7.50 | 24.81 ± 6.89 | 15.42 ± 9.23 | 12.19 ± 8.71 | 6.75 ± 9.11 | 21.50 ± 4.58 | 13.70 ± 8.04 | 13.08 ± 3.09 | 9.87 ± 4.66 | |
Sig. | < 0.001a | 0.064 | < 0.001a | 0.017 | < 0.001a | 0.418 | < 0.001a | 0.162 | 0.007a | 0.038 |
Table 3 Association of the number of high-level stress-sensitivity factors with clinical manifestations and follow-up outcomes in major depressive disorders
Items | Time | All factors Partial eta-squared (η2) | Sig. | PSS + S-AI Partial eta-squared (η2) | Sig. | Neuroticism + T-AI partial eta-squared (η2) | Sig. |
HAMD-17 | Baseline | 0.158 | < 0.001a | 0.153 | < 0.001a | 0.085 | < 0.001a |
At the end of follow-up | NA | NA | NA | NA | 0.204 | < 0.001a | |
HAMA | Baseline | 0.145 | < 0.001a | 0.129 | < 0.001a | 0.072 | < 0.001a |
At the end of follow-up | NA | NA | NA | NA | 0.155 | < 0.001a | |
BSSI | Baseline | 0.160 | < 0.001a | 0.117 | < 0.001a | 0.135 | < 0.001a |
At the end of follow-up (n = 66) | NA | NA | NA | NA | 0.156 | 0.002a | |
SDS | Baseline | 0.240 | < 0.001a | 0.132 | < 0.001a | 0.145 | < 0.001a |
At the end of follow-up | NA | NA | NA | NA | 0.072 | 0.003a | |
PDQ-5 | Baseline | 0.138 | < 0.001a | 0.065 | < 0.001a | 0.066 | < 0.001a |
At the end of follow-up | NA | NA | NA | NA | 0.143 | < 0.001a |
Table 4 Multivariable regression analysis of depressive symptoms and suicide risk
- Citation: Qin XM, Xu MQ, Qin YQ, Shao FZ, Ma MH, Ou WW, Lv GY, Zhang QQ, Chen WT, Zhao XT, Deng AQ, Xiong JT, Zeng LS, Peng YL, Huang M, Xu SY, Liao M, Zhang L, Li LJ, Ju YM, Liu J, Liu BS, Zhang Y. Cumulative effects of stress-sensitivity factors on depressive symptoms and suicide risk: A prospective study. World J Psychiatry 2025; 15(2): 99996
- URL: https://www.wjgnet.com/2220-3206/full/v15/i2/99996.htm
- DOI: https://dx.doi.org/10.5498/wjp.v15.i2.99996